Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Pyxis Oncology Inc

Healthcare US PYXS

2.77USD
0.54(24.22%)

Last update at 2026-06-26T20:24:00Z

Day Range

2.203.00
LowHigh

52 Week Range

1.356.85
LowHigh

Fundamentals

  • Previous Close 2.23
  • Market Cap220.24M
  • Volume6856165
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-78.49300M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.34

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -120.71700M -75.97500M -12.82800M -2.77200M
Minority interest - - - -
Net income -117.95300M -81.53600M -12.76200M -2.66500M
Selling general administrative 37.35M 18.66M 3.85M 1.66M
Selling and marketing expenses - - - -
Gross profit - - - -
Reconciled depreciation 0.71M 0.65M 0.47M 0.00000M
Ebit -124.19000M -69.71700M -12.89400M -2.87900M
Ebitda -123.48100M -63.48600M -12.42500M -2.87900M
Depreciation and amortization 0.71M 6.23M 0.47M 0.11M
Non operating income net other 2.76M -6.25800M - -
Operating income -123.48100M -69.71700M -12.89400M -2.87900M
Other operating expenses 123.48M 69.72M 12.89M 2.88M
Interest expense 2.76M 6.26M 0.00000M 0.00000M
Tax provision - - - -
Interest income 2.76M 0.02M 0.07M 0.11M
Net interest income 2.76M 0.02M 0.07M 0.11M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense -2.76400M 5.56M -0.06600M -0.10700M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 123.48M 69.72M 12.89M 2.88M
Cost of revenue - - - -
Total other income expense net 2.76M -6.25800M 0.07M 0.11M
Discontinued operations - - - -
Net income from continuing ops -120.71700M -75.97500M -12.82800M -2.77200M
Net income applicable to common shares -120.71700M -75.97500M -12.82800M -2.77200M
Preferred stock and other adjustments - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 173.73M 211.38M 280.02M 10.15M 19.81M
Intangible assets 24.31M - - - -
Earning assets - - - - -
Other current assets 3.81M 5.85M 2.47M 0.01M 0.01M
Total liab 48.02M 50.55M 18.71M 25.80M 22.68M
Total stockholder equity 125.70M 160.82M 261.31M -15.64500M -2.87400M
Deferred long term liab - - - - -
Other current liab 12.97M 24.54M 0.27M 0.05M 0.00900M
Common stock 0.04M 0.03M 0.03M 0.00100M 0.00100M
Capital stock 0.04M 0.03M 0.03M 0.00100M 0.00100M
Retained earnings -286.22500M -212.43500M -91.71800M -15.74300M -2.91500M
Other liab - - - - -
Good will - - - - -
Other assets - - 0.11M 0.11M 0.03M
Cash 11.14M 179.29M 274.74M 8.08M 19.69M
Cash and equivalents - - - - -
Total current liabilities 25.76M 31.63M 18.71M 3.69M 0.73M
Current deferred revenue 7.66M - 6.33M 1.95M 0.22M
Net debt 10.20M -160.37200M -274.57000M -7.30000M -19.67500M
Short term debt 1.23M - 0.17M 0.61M 0.00900M
Short long term debt - - - - -
Short long term debt total 21.33M 18.92M 0.17M 0.78M 0.01M
Other stockholder equity 411.82M 373.23M 353.00M 0.10M 0.04M
Property plant equipment - 11.16M 1.01M 1.94M 0.08M
Total current assets 124.60M 186.61M 278.67M 8.10M 19.70M
Long term investments - - - - -
Net tangible assets - 160.82M 261.31M -15.64500M -2.87400M
Short term investments 109.63M - - - -
Net receivables 0.02M 0.60M - - -
Long term debt - - - - -
Inventory - 0.87M - - -
Accounts payable 3.90M 7.10M 11.95M 1.08M 0.49M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.06M - -280.02100M - -
Additional paid in capital - - - - -
Common stock total equity - 0.03M 0.03M - -
Preferred stock total equity - - - - -
Retained earnings total equity - -212.43500M -91.71800M - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 13.60M 0.11M 0.11M 0.03M
Deferred long term asset charges - - - - -
Non current assets total 49.12M 24.77M 1.35M 2.05M 0.11M
Capital lease obligations 21.33M 18.92M 0.17M 0.78M 0.01M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -6.39900M -0.05000M -1.48300M -0.05000M
Change to liabilities 3.62M 9.73M 0.56M 0.29M
Total cashflows from investing activities -6.39900M -0.59000M -1.48300M -1.48300M
Net borrowings - - - -
Total cash from financing activities 0.18M 304.04M 0.04M 21.95M
Change to operating activities - 2.03M 1.73M 0.21M
Net income -120.71700M -75.97500M -12.82800M -2.77200M
Change in cash -95.55100M 268.13M -11.53200M 19.72M
Begin period cash flow 276.32M 8.19M 19.72M 0.00400M
End period cash flow 180.76M 276.32M 8.19M 19.72M
Total cash from operating activities -89.33500M -35.32600M -10.08400M -2.23900M
Issuance of capital stock 0.00000M 303.88M 0.04M 21.95M
Depreciation 0.71M 0.65M 0.47M 0.47M
Other cashflows from investing activities - - - -
Dividends paid - - - -
Change to inventory - - - -
Change to account receivables - - - -
Sale purchase of stock 0.18M 304.04M - -
Other cashflows from financing activities -6.39900M 151.75M -1.48300M 21.94M
Change to netincome 15.76M 32.67M -0.01200M 0.03M
Capital expenditures 6.40M 0.54M 1.48M 1.48M
Change receivables - - - -
Cash flows other operating 11.29M -2.40500M - -
Exchange rate changes - - - -
Cash and cash equivalents changes -95.55100M 268.13M - -
Change in working capital 4.50M 6.68M 2.29M 0.51M
Stock based compensation 15.76M 6.44M 0.04M 0.03M
Other non cash items 10.41M 20.60M -0.05600M -
Free cash flow -95.73400M -35.86600M -11.56700M -2.23900M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
PYXS
Pyxis Oncology Inc		 0.54 24.22% 2.77 - - - 2.29 -2.3572
NVO
Novo Nordisk A/S		 0.43 0.90% 48.07 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 47.84 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 11.16 2.32% 491.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 12.76 2.06% 632.90 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Pyxis Oncology Inc

150 Cambridgepark Drive, Cambridge, MA, United States, 02140

Key Executives

Name Title Year Born
Mr. John L. Flavin M.B.A., MBA, Ph.D. Co-Founder & Independent Chairman 1971
Dr. Lara S. Sullivan M.D., MBA CEO, Pres & Director NA
Ms. Pamela Yanchik Connealy M.B.A. Chief Financial Officer 1962
Dr. Jay M. Feingold M.D., Ph.D. Chief Medical Officer 1957
Mr. Jitendra Wadhane Chief Accounting Officer, Sr. VP of Fin. & Corp. Controller 1980
Dr. Balu N. Balasubramanian Ph.D. Interim Chief Technology Officer NA
Dr. Jan Pinkas Ph.D. Chief Scientific Officer NA
Ms. Martina Molsbergen B.S. Interim Chief Bus. Officer 1965
Dr. Charles T. Gombar Ph.D. Sr. VP of Portfolio & Program Management NA
Dr. Lara S. Sullivan M.D., MBA CEO, President & Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.